
The phase I development program of zzso and zzso zzso in the United States has included evaluation of the drug as a single agent and subsequent studies of its zzso zzso by oral zzso Phase I trials of zzso zzso examined both a zzso schedule repeated every 21 days and a zzso schedule repeated every 35 zzso In all of the trials the total dose was divided by three and administered three times daily at zzso zzso Like intravenous schedules of zzso zzso zzso has zzso zzso with zzso being the zzso toxicity for the zzso regimen and zzso being the zzso toxicity for the zzso zzso The suggested phase II doses for zzso administered without zzso were 800 zzso for the zzso schedule and 360 zzso for the zzso zzso zzso phase I studies combining zzso with oral zzso used a zzso schedule repeated every 35 zzso zzso was the zzso zzso and the recommended phase II dose was zzso 300 zzso plus zzso 90 zzso zzso evaluation showed that zzso zzso results in maximum plasma levels and an area under the zzso curve that increased with escalating zzso zzso In addition, zzso levels were zzso throughout the zzso dosing zzso however, there was no evidence of significant zzso of zzso zzso or zzso The administration of zzso in this trial provided continuous exposure of zzso and zzso with little variation between doses or zzso 

